SeaStar announces enrollment in NEURTALIZE-AKI trial passes halfway point

SeaStar Medical (ICU) announces that 51 subjects have been enrolled in its NEUTRALIZE-AKI pivotal trial, passing the halfway point toward the target of 100 subjects for performing an interim analysis on the trial’s 90-day primary endpoint. The trial is evaluating the safety and efficacy of SeaStar Medical’s proprietary therapeutic Selective Cytopheretic Device, SCD, in adults with acute kidney injury, AKI, in the intensive care unit, ICU, receiving continuous kidney replacement therapy, CKRT.